Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

New accessible multiplex imaging workflow advances spatial liver research

Spatial biology technologies are reshaping modern biomedical research by enabling the visualization of cellular organization and interactions within intact tissues.

26 Jun 2026

Synthetic protein hybrid offers promising treatment for liver diseases

The research group led by CIC biomaGUNE's Ikerbasque Research Professor Aitziber L. Cortajarena has developed an innovative anti-fibrotic and anti-tumor treatment by binding a synthetic protein to gold nanoclusters (small aggregates of approximately 6 atoms of gold).

23 Jun 2026

Immunotherapy helps bridge cancer patients to curative liver transplantation

Liver transplantation remains one of the most powerful curative options for hepatocellular carcinoma (HCC) because it removes both the tumor and the diseased liver.

22 Jun 2026

Understanding mitochondrial biology in alcohol-associated liver disease and cancer

For decades, giant mitochondria-known as megamitochondria-have been recognized in liver biopsies from patients with alcohol-associated liver disease (ALD).

1 Jun 2026

Ferroptosis exploits unique cancer metabolic vulnerabilities to bypass traditional apoptotic evasion pathways

A new wave of scientific understanding is placing ferroptosis, a distinct form of iron-dependent cell death, at the forefront of efforts to overcome drug resistance in digestive cancers. These cancers, which include gastric, colorectal, liver, pancreatic, and esophageal malignancies, remain among the most challenging to treat due to their ability to evade standard therapies.

25 May 2026

Sequential TACE after SBRT improves outcomes in recurrent hepatocellular carcinoma

Comparative data on sequential transarterial chemoembolization (TACE) after stereotactic body radiation therapy (SBRT) in recurrent hepatocellular carcinoma (HCC) remain limited. This study aimed to evaluate the efficacy of this combination.

13 May 2026

WHO report shows measurable progress in reducing global hepatitis infections

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a new World Health Organization (WHO) report released today at the World Hepatitis Summit.

28 Apr 2026

Study identifies key risk factors driving MASLD across populations

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population.

23 Apr 2026

AGA update calls for better surveillance of hepatocellular carcinoma

A new update from the American Gastroenterological Association (AGA) urges stronger prevention efforts and better early-detection tools for hepatocellular carcinoma (HCC), the leading cause of cancer-related death in patients with cirrhosis, and the third most common cause of cancer-related death worldwide.

17 Apr 2026

New roadmap links liver cancer biology to immunotherapy and precision medicine

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide.

17 Apr 2026

Liver cancer burden rising globally amid shift to metabolic risks

Primary liver cancer continues to pose a major global health challenge, ranking as the third leading cause of cancer-related deaths worldwide.

15 Apr 2026

Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy due to their innate capacity for self-renewal and differentiation.

11 Apr 2026

Gene signature maps cholangiocarcinoma subtypes for precision treatment

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly concealed and heterogeneous nature.

31 Mar 2026

Gut-derived metabolites regulate immune cells in complex ways

Published on March 23, 2026, in Volume 2, article number 18 of the journal Immunity & Inflammation, the review begins by systematically outlining the sources and synthetic pathways of immune-relevant microbial metabolites, including bile acids, short-chain fatty acids, amino acid derivatives, vitamins, trimethylamine/trimethylamine N-oxide, and odd-chain fatty acids.

31 Mar 2026

New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma

The 1,341-gene signature for intrahepatic cholangiocarcinoma offers a framework for precise diagnosis and tailored therapies, addressing tumor heterogeneity.

From BGI Genomics 31 Mar 2026

Machine learning model predicts liver cancer risk with high accuracy

A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high accuracy.

26 Mar 2026

Tiny gene mutations shape cancer behavior and immune response

Cancer is often thought of as a single disease. Yet even tumors that arise in the same organ can follow very different genetic paths.

19 Mar 2026

Expert consensus validates UDFF for noninvasive fatty liver assessment

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

17 Mar 2026

New insight into origins of rare liver tumors in children

Liver cancer in children is rare, but when it occurs the two main types are hepatoblastoma (HB) and hepatocellular carcinoma (HCC).

16 Mar 2026

EVA1A regulates fatty acid transporter CD36 in fatty liver disease

Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, obesity, and diabetes prevalence, making it one of the most common chronic liver diseases worldwide.

9 Mar 2026